References
- Bruneau P. (2001). Search for predictive generic model of aqueous solubility using Bayesian neural networks. J Chem Inf Comput Sci 41:1605–16
- Burckhardt G. (2012). Drug transport by organic anion transporters. Pharm Ther 136:106–30
- Burckhardt G, Burckhardt BC. (2011). In vitro and in vivo evidence of the importance of organic anion transporters (OATs) in drug therapy. In: Fromm MF, Kim R, eds. Drug transporters, handbook of experimental pharmacology. Berlin, Heidelberg: Springer-Verlag, 29–102
- Chang G, Varma MV. (2010). Renal clearance in drug discovery and development: molecular descriptors, drug transporters and disease state. Expert Opin Drug Metab Toxicol 6:939–52
- Chohan KK, Paine SW, Mistry J, et al. (2005). A rapid computational filter for cytochrome P450 1A2 inhibition potential of compound libraries. J Med Chem 48:5154–61
- DeGorter MK, Xia CQ, Jang JJ, Kim RB. (2012). Drug transporters in drug efficacy and toxicity. Ann Rev Pharmacol Toxicol 52:249–73
- Di L, Keefer C, Scott DO, et al. (2012). Mechanistic insights from comparing intrinsic clearance values between human liver microsomes and hepatocytes to guide drug design. Eur J Med Chem 57:441–8
- Fessey RE, Austin RP, Barton P, et al. (2006). The role of plasma protein binding in drug discovery. In: Testa B, Krämer SD, Wunderli-Allenspach H, Folkers G, eds. Pharmacokinetics profiling in drug research. Weinheim, Germany: Wiley-VCH, 119–41
- Hansch C, Leo A, Elkins D. (1971). Partition coefficients and their uses. Chem Rev 71:525–616
- Karlgren M, Vildhede A, Norinder U, et al. (2012). Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug--drug interactions. J Med Chem 55:4740–63
- Khanna I. (2012). Drug discovery in pharmaceutical industry: productivity challenges and trends. Drug Discov Today 17:1088–102
- Kusuhara H, Sekine T, Utsunomiya-Tate N, et al. (1999). Molecular cloning and characterization of a new multispecific organic anion transporter from rat brain. J Biol Chem 274:13675–80
- Lai Y, Sampson KE, Balogh LM, et al. (2010). Preclinical and clinical evidence for the collaborative transport and renal secretion of an oxazolidinone antibiotic by organic anion transporter 3 (OAT3/SLC22A8) and multidrug and toxin extrusion protein 1 (MATE1/SLC47A1). J Pharm Exp Ther 334:936–44
- Mahmood I. (1998). Interspecies scaling of renally secreted drugs. Life Sci 63:2365–71
- Masereeuw R, Russel FG. (2010). Therapeutic implications of renal anionic drug transporters. Pharmacol Ther 126:200–16
- McGinnity DF, Collington J, Austin RP, Riley RJ. (2007). Evaluation of human pharmacokinetics, therapeutic dose and exposure predictions using marketed oral drugs. Curr Drug Metab 8:463–79
- Obach RS. (1999). Prediction of human clearance of twenty-nine drugs from hepatic microsomal intrinsic clearance data: an examination of in vitro half-life approach and nonspecific binding to microsomes. Drug Metab Dispos 27:1350–9
- Paine SW, Barton P, Bird J, et al. (2010). A rapid computational filter for predicting the rate of human renal clearance. J Mol Graph Model 29:529–37
- Paine SW, Ménochet K, Denton R, et al. (2011). Prediction of human renal clearance from preclinical species for a diverse set of drugs that exhibit both active secretion and net reabsorption. Drug Metab Dispos 39:1008–13
- Paul SM, Mytelka DS, Dunwiddle CT, et al. (2010). How to improve R&D productivity: the pharmaceutical industry’s grand challenge. Nat Rev Drug Discov 9:203–14
- Raevsky OA, Schaper KJ. (1998). Quantitative estimation of hydrogen bond contribution to permeability and absorption processes of some chemicals and drugs. Eur J Med Chem 33:799–809
- Riley RJ, McGinnity DF, Austin RP. (2005). A unified model for predicting human hepatic, metabolic clearance from in vitro intrinsic clearance data in hepatocytes and microsomes. Drug Metab Dispos 33:1304–11
- Smith DA, Brown K, Neale MG. (1985). Chromone-2-carboxylic acids: roles of acidity and lipophilicity in drug disposition. Drug Metab Rev 16:365–88
- Soars MG, Grime K, Sproston JL, et al. (2007). Use of hepatocytes to assess the contribution of hepatic uptake to clearance in vivo. Drug Metab Dispos 35:859–65
- Soars MG, Barton P, Ismair M, et al. (2012). The development, characterization, and application of an OATP1B1 inhibition assay in drug discovery. Drug Metab Dispos 40:1641–8
- Tahara H, Shono M, Kusuhara H, et al. (2005). Molecular cloning and functional analyses of OAT1 and OAT3 from cynomolgus monkey kidney. Pharm Res 22:647–60
- van De Waterbeemd H, Smith DA, Beaumont K, Walker DK. (2001). Property-based design: optimization of drug absorption and pharmacokinetics. J Med Chem 44:1313–33
- Varma MV, Feng B, Obach RS, et al. (2009). Physicochemical determinants of human renal clearance. J Med Chem 52:4844–52
- Verloop A, Tipker J. (1987). Physical basis of sterimol and related steric constants. In: Hadzi B, Jerman-Blazic B, eds. Pharmaco chemistry library, QSAR in drug dosing and toxicology. Amsterdam: Elsevier, Vol. 10, 97–102
- Wei Y, Xi L, Yao X, et al. (2012). Quantitative structure--activity relationship analysis of a series of human renal organic anion transporter inhibitors. Arch Pharm Chem Life Sci 345:759–66
- Wempe MF, Jutabha P, Quade B, et al. (2011). Developing potent human uric acid transporter 1 (hURAT1) inhibitors. J Med Chem 54:2701–13
- Wilby AJ, Maeda K, Courtney PF, et al. (2011). Hepatic uptake in the dog: comparison of uptake in hepatocytes and human embryonic kidney cells expressing dog organic anion-transporting polypeptide 1B4. Drug Metab Dispos 39:2361–9
- Wolman AT, Gionfriddo MR, Heindel GA, et al. (2013). Organic anion transporter 3 interacts selectively with lipophilic β-lactam antibiotics. Drug Metab Dispos 41:791–800